---

AGOMELATINE & ETIFOXINE - Complete Clinical Pharmacology Guide

---

PART I: AGOMELATINE (Valdoxan / Thymanax)

---

1. Introduction & Background

---

2. Mechanism of Action

• Agonist at melatonin MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN)
• Resynchronizes circadian rhythms - acts as "substitute melatonin" even when pineal melatonin production is reduced (as seen in depression)
• Resets the biological clock, improving the sleep-wake cycle and promoting deep slow-wave sleep
• (Stahl's Essential Psychopharmacology, Figure 7-39)

• Antagonist at serotonin 5-HT2C receptors in the VTA and locus coeruleus
• By blocking 5-HT2C receptors, agomelatine disinhibits dopamine and norepinephrine release in the prefrontal cortex - this is considered the primary antidepressant mechanism
• 5-HT2C blockade in the SCN also contributes to circadian resynchronization

• No effect on monoamine (serotonin, norepinephrine, dopamine) reuptake transporters
• No affinity for adrenergic, histaminergic, cholinergic, or dopaminergic receptors
• No benzodiazepine receptor activity
• (Maudsley Deprescribing Guidelines; Kaplan & Sadock's)

---

3. Pharmacokinetics

---

4. Pharmacodynamics (Clinical)

• Onset of antidepressant effect: typically 2 weeks (sleep improvement often seen earlier)
• Improves slow-wave sleep (SWS/NREM), reduces sleep latency
• Does not cause daytime sedation or cognitive impairment
• No weight gain, sexual dysfunction, or discontinuation syndrome (in formal trials - though informal reports exist)
• Dose-response: hyperbolic relationship between dose and MT1/MT2 receptor occupancy

---

5. Indications

• Treatment of major depressive episodes (MDE) in adults
• Prevention of relapse of MDE (Australia PI, 2024)

• Generalized Anxiety Disorder (GAD) - studied, some evidence
• Seasonal Affective Disorder (SAD)
• Depression with prominent sleep disturbance
• Bipolar depression (adjunctive, limited evidence)
• Sleep disorders / insomnia accompanying psychiatric illness (Goodman & Gilman's)

---

6. Dosing & Formulations

• Starting dose: 25 mg once daily at bedtime
• Dose escalation: After 2 weeks, if inadequate response, increase to 50 mg once daily at bedtime
• The bedtime timing is mandatory - it mimics physiological melatonin secretion and aligns the circadian reset

• Tablets: 25 mg (available in UK, Europe, Australia, India)
• No 50 mg tablet commercially available - 50 mg dose is given as two 25 mg tablets
• Not available in the USA

• Tablets may be split or crushed (coating has minimal effect on absorption)
• A 1 mg/mL suspension can be prepared by dissolving a 25 mg tablet in 25 mL water - use immediately, do not store

---

7. Liver Function Test (LFT) Monitoring Protocol

• Transaminases exceed 3x the upper limit of normal (ULN)
• Any symptoms of hepatic injury (jaundice, fatigue, right upper quadrant pain, dark urine)

---

8. Side Effects

• Headache (most common)
• Nausea
• Dizziness
• Somnolence / fatigue
• Diarrhea or constipation
• Back pain, abdominal pain

• Elevated transaminases: 1.4% at 25 mg and 2.5% at 50 mg (>3x ULN) in clinical trials
• Rare: hepatitis, jaundice, gamma-GT elevation, hepatic failure
• Risk factors: obesity, non-alcoholic fatty liver disease (NAFLD), diabetes, excessive alcohol use
• (Kaplan & Sadock's Comprehensive Textbook of Psychiatry)

• Sexual dysfunction (major advantage over SSRIs/SNRIs)
• Weight gain
• QTc prolongation
• Anticholinergic effects
• Cognitive impairment
• Orthostatic hypotension
• Sedation / next-day hangover
• Hyponatraemia (unlike SSRIs - important in elderly)

---

9. Contraindications

1. Hepatic impairment (cirrhosis or active liver disease)
2. Transaminases >3x ULN at baseline
3. Concurrent potent CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) - ABSOLUTE contraindication
4. Hypersensitivity to agomelatine or excipients
5. Not recommended in patients <18 years (no established evidence)
6. Not licensed in patients ≥75 years (no efficacy data)

---

10. Precautions

• Excessive alcohol or substance misuse (hepatotoxicity risk)
• Obesity, NAFLD, diabetes (hepatic risk factors)
• Bipolar disorder / history of mania or hypomania
• Personal or family history of seizures
• Suicidal ideation (monitor especially at treatment initiation)
• Moderate CYP1A2 inhibitors (e.g., propranolol, oestrogens): use with caution, not contraindicated
• Heavy smokers: reduced efficacy (CYP1A2 induction by tobacco)

---

11. Drug Interactions

---

12. Special Populations

• Efficacy and safety established (25-50 mg/day)
• Network meta-analysis rates agomelatine among the highest efficacy antidepressants in the elderly (along with duloxetine, quetiapine, vortioxetine) (Maudsley Prescribing Guidelines 15th ed.)
• Key advantage: No hyponatraemia risk (unlike SSRIs), no orthostatic hypotension, no QTc prolongation, no anticholinergic effects
• Limitation: frequent blood sampling for LFTs is burdensome
• Not licensed in ≥75 years (no efficacy data)

• Classified as Pregnancy Category C (Australia) / Not recommended
• No adequate human data; cross placenta in animal studies
• No formal teratogenicity trials
• Clinical judgment required: risk-benefit discussion

• Not recommended; animal data shows excretion in breast milk

• Not recommended; clinical trials did not show efficacy in adolescents; increased suicidality risk noted (similar to all antidepressants in youth)

• Contraindicated in any degree of hepatic impairment
• Free drug fraction doubles in hepatic impairment; metabolic clearance severely reduced

• No dose adjustment needed (agomelatine metabolites are excreted in urine, but the parent drug metabolism is not affected by renal function)
• Kaplan & Sadock's: "No evidence that clearance is altered by preexisting renal impairment"

---

13. Discontinuation

• Informal reports and pharmacovigilance signals suggest some patients do experience discontinuation symptoms
• The Maudsley Deprescribing Guidelines recommend hyperbolic tapering rather than abrupt discontinuation, based on the pharmacological principle that receptor occupancy follows a hyperbolic dose-response curve
• Linear dose reductions create progressively larger pharmacological shifts; hyperbolic reductions (e.g., 25 mg → 12.5 mg → 6.25 mg → 3 mg → stop) create equal steps in receptor occupancy terms
• Practice: Taper over several weeks when discontinuing

---

14. Toxicity / Overdose

• Limited overdose data
• Reports of doses up to 450-750 mg in deliberate self-poisoning with no serious sequelae
• Most common overdose features: somnolence, agitation, nausea, epigastric pain
• No specific antidote; supportive management
• Hepatic monitoring post-overdose is prudent

---

15. Guidelines Summary

NICE (UK):

• Agomelatine was evaluated through the NICE single technology appraisal (TA231) process
• Current NICE depression guideline (NG222, 2022) does not specifically position agomelatine above other antidepressants; SSRI (sertraline) remains first-line
• Agomelatine is positioned as a 2nd or 3rd line option when SSRIs/SNRIs fail or are not tolerated, especially when sexual side effects or sleep disturbance are prominent concerns
• Nottinghamshire APC (2024): Agomelatine classified as "Amber 2" - 4th-line option where other antidepressants have failed

CANMAT 2023 (Canada):

• Agomelatine listed as a Line 2 antidepressant (behind SSRIs/SNRIs as Line 1)
• Specifically recommended as first-line for patients with MDD + prominent sleep disturbance
• Also recommended when sexual side effects of other antidepressants are problematic
• Recommended in patients who failed prior SSRI/SNRI

Chinese Guidelines (2015, 2nd ed.):

• Agomelatine recommended as first-line for depression with sleep disorders
• Web search confirmed this positioning

Indian Practice:

• Not included in formal IPGTR (Indian Psychiatric Society Guidelines) for first-line treatment
• Available as Valdoxan in India
• Widely used in clinical practice as 2nd/3rd line when SSRIs cause sexual dysfunction or significant sleep disruption
• Prescribed per EMA SPC guidelines (liver monitoring mandatory)

APA (American Psychiatric Association):

• APA does not include agomelatine in its official guidelines as the drug is not FDA-approved in the USA
• Clinicians in India/Europe use CANMAT and EMA guidance

---

16. Key Clinical Trials (Evidence Base)

---

---

PART II: ETIFOXINE (Stresam)

---

1. Introduction & Background

---

2. Mechanism of Action (Dual, Unique)

Mechanism 1: Direct GABA-A Receptor Positive Allosteric Modulation

• Binds directly to the β2/β3 subunits of the GABA-A receptor complex (NOT the benzodiazepine binding site at the α-γ interface)
• Acts as a positive allosteric modulator, enhancing chloride conductance
• Affinity is in the micromolar range (weaker than BZDs which act in the nanomolar range)
• This site difference explains why etifoxine's effects are not fully reversed by flumazenil (benzodiazepine antagonist)

Mechanism 2: TSPO Activation → Neurosteroidogenesis

• Binds to the 18 kDa Translocator Protein (TSPO) on the outer mitochondrial membrane (previously called "peripheral benzodiazepine receptor")
• TSPO activation stimulates transport of cholesterol into mitochondria → rate-limiting step for neurosteroid synthesis
• Results in increased synthesis of allopregnanolone (3α,5α-THDP) and other 3α-reduced neurosteroids
• Allopregnanolone is an endogenous, highly potent positive allosteric modulator of GABA-A receptors
• This indirect neurosteroidogenic mechanism creates a synergistic, sustained GABAergic enhancement

• Neuroprotective effects
• Anti-inflammatory properties
• Neuroplastic effects
• Possibly antidepressant (proof-of-concept trial ongoing, 2023-2026)
• (EMA Article 31 Assessment; PMC6615018; Springer Trials 2024)

---

3. Pharmacokinetics

---

4. Pharmacodynamics (Clinical)

• Onset: anxiolytic effect within 1-3 hours of dosing
• No tolerance development observed in clinical trials (up to 12 weeks)
• No dependence or withdrawal syndrome reported in pharmacovigilance data over 30+ years
• No significant cognitive impairment (unlike benzodiazepines)
• No amnesia; no psychomotor impairment at therapeutic doses
• Mild sedation (mainly at initiation) compared to benzodiazepines

---

5. Indications

• Symptomatic treatment of anxiety in adults
• Specifically studied for Adjustment Disorder with Anxiety (ADWA)

• Generalized Anxiety Disorder (GAD)
• Pain with anxiety (studied in chronic pain populations)
• Peripheral nerve repair / neuroprotection (TSPO-related)
• Depression (proof-of-concept, ongoing 2023-2026 study)

---

6. Dosing & Formulations

• Recommended dose: 150 mg/day (3 x 50 mg capsules divided into 2-3 doses)
• Maximum dose: 200 mg/day (4 x 50 mg capsules) in 2-3 divided doses
• Duration: Limited to a few days to a few weeks (up to 12 weeks maximum)
• Can be taken with or without food

---

7. Side Effects

• Drowsiness / somnolence (most frequent; mainly at initiation; mild)
• Fatigue / sedation (less than benzodiazepines)

• Elevated liver enzymes (transaminases) - incidence unknown; reversible on discontinuation
• Rare hepatobiliary disorders reported in pharmacovigilance
• LFT monitoring recommended periodically

• Skin and subcutaneous reactions (toxidermia) - rare; resolve with discontinuation

• Anterograde amnesia
• Significant cognitive or psychomotor impairment
• Rebound anxiety
• Dependence or withdrawal
• Tolerance
• (PMC6615018; EMA CHMP report)

• STRETI trial: 35% AE rate (etifoxine) vs 47.5% (alprazolam)
• CNS symptoms (somnolence, sedation, fatigue): 16% (etifoxine) vs 24.8% (alprazolam)
• Severe AEs: 1 (etifoxine) vs 4 (alprazolam)

---

8. Contraindications

1. Shock (cardiovascular shock)
2. Severe hepatic impairment / active liver disease
3. Severe renal impairment
4. Severe respiratory failure
5. Hypersensitivity to etifoxine or excipients
6. Pregnancy (crosses the placenta; not recommended - Pregnancy Category: Not recommended)
7. Breastfeeding (excreted in milk)
8. Children and adolescents (<18 years) - not established

---

9. Precautions

• Mild-moderate hepatic or renal impairment: use with caution; monitor LFTs
• Avoid in patients with history of alcohol/substance use disorder (though dependence risk lower than BZDs)
• Driving/operating machinery: mild sedation may impair performance, especially initially
• Periodic LFT monitoring recommended during therapy

---

10. Drug Interactions

• CNS depressants (alcohol, opioids, other sedatives): additive CNS depression
• Flumazenil: Only partial reversal of sedative effects (since binding site differs from BZDs)
• No documented significant pharmacokinetic drug-drug interactions in the literature
• Caution with hepatotoxic drugs (additive liver risk)

---

11. Special Populations

• Crosses placenta; animal data showed some effects
• Not recommended - insufficient human safety data

• Excreted in breast milk; not recommended

• Limited specific data; start at lower end of dose range; monitor for sedation
• Favorable compared to BZDs (no cognitive impairment, no fall risk from psychomotor impairment)

• Not established; not recommended

• Severe: contraindicated
• Mild-moderate: use with caution, monitor LFTs

• Severe: contraindicated
• Mild-moderate: use with caution

---

12. Discontinuation

• No withdrawal syndrome reported in pharmacovigilance over 30 years of use (major advantage over BZDs)
• No rebound anxiety on stopping
• No dependence observed in clinical studies
• Treatment is time-limited by design (few days to weeks, max 12 weeks)
• Can be stopped abruptly without tapering - though gradual reduction is still reasonable practice

---

13. Toxicity / Overdose

• Toxicity profile is favorable with no reports of serious overdose complications at standard doses
• In overdose: mainly drowsiness, sedation
• No respiratory depression (unlike BZDs - no direct GABA-A benzodiazepine site action at high doses)
• Supportive management; monitor hepatic function

---

14. Guidelines Summary

Indian Psychiatry:

• No formal IPGTR (Indian Psychiatric Society) guideline specifically endorses etifoxine as first-line
• Kaplan & Sadock's notes it as a comparator superior to benzodiazepines and buspirone for adjustment disorder with anxiety
• Increasingly used in India for short-term anxiety management, particularly as an alternative to benzodiazepines (concerns about BZD misuse in India)
• Most commonly positioned in Adjustment Disorder with Anxiety, short-term GAD

European/International:

• EMA Article 31 referral (published): Confirmed etifoxine's evidence base; reviewed post-authorisation studies (STRETI, ETILOR, ETIZAL) - all showing non-inferiority to BZDs with better tolerability
• Licensed in France and several EU countries for anxiety
• Not approved by NICE (UK), FDA (USA)

APA:

• APA does not include etifoxine (not FDA-approved)

NICE (UK):

• Not licensed or recommended; no NICE appraisal

---

15. Key Clinical Trials (Evidence Base)

---

Comparative Summary: Agomelatine vs Etifoxine

---

Key References

• Stahl's Essential Psychopharmacology (Figure 7-39: agomelatine circadian mechanism)
• The Maudsley Deprescribing Guidelines - Agomelatine tapering protocol
• The Maudsley Prescribing Guidelines in Psychiatry, 15th ed. - Older adults, hepatic impairment
• Kaplan & Sadock's Comprehensive Textbook of Psychiatry - Drug interactions, etifoxine in ADWA
• Goodman & Gilman's Pharmacological Basis of Therapeutics - Melatonin receptor agonists
• Nuss P. et al. (2019) - "An update on the anxiolytic and neuroprotective properties of etifoxine" [PMC6615018]
• Kishi T. et al. (2023) - Antidepressant maintenance meta-analysis [PMID: 36253442]
• Ju Y. et al. (2025) - Agomelatine adjunctive RCT [PMID: 40038707]
• Gédek A. et al. (2024) - Agomelatine in diabetes + depression [PMID: 39684343]
• Prabhakar K. et al. (2026) - Indian Phase III etifoxine RCT [PMID: 41763071]
• EMA Article 31 Assessment Report - Etifoxine
• Agomelatine SmPC (EMA/Australia 2024)